Evidence map›Paper›PMID 40303042›Full record

ArticleTransboundary and emerging diseases2024

No Evidence of SARS-CoV-2 Infection in Urban Wildlife of Hokkaido, Japan.

Anastasiia Kovba, Naganori Nao, Michito Shimozuru, Mariko Sashika, Chihiro Takahata, Kei Sato, Keiya Uriu, Masami Yamanaka, Masanao Nakanishi, Genta Ito and 7 more

Abstract read
In one paragraph

Article in Transboundary and emerging diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Anastasiia KovbaGraduate School of Veterinary Medicine Hokkaido University, Kita 18, Nishi 9, Kita-ku, Sapporo City 060-0818, Hokkaido, Japan.ORCID https://orcid.org/0009-0002-4884-7350
Naganori NaoInstitute for Vaccine Research and Development HU-IVReD Hokkaido University, Kita 21, Nishi 11, Kita-ku, Sapporo City 001-0021, Hokkaido, Japan.
Michito ShimozuruOne Health Research Center Hokkaido University, Kita 18, Nishi 9, Kita-ku, Sapporo City 060-0818, Hokkaido, Japan.
Mariko SashikaFaculty of Veterinary Medicine Hokkaido University, Kita 18, Nishi 9, Kita-ku, Sapporo City 060-0818, Hokkaido, Japan.ORCID https://orcid.org/0000-0002-0649-7578
Chihiro TakahataFaculty of Veterinary Medicine Hokkaido University, Kita 18, Nishi 9, Kita-ku, Sapporo City 060-0818, Hokkaido, Japan.
Kei SatoDivision of Systems Virology Department of Microbiology and Immunology The Institute of Medical Science The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku 108-8639, Tokyo, Japan.
Keiya UriuDivision of Systems Virology Department of Microbiology and Immunology The Institute of Medical Science The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku 108-8639, Tokyo, Japan.
Masami YamanakaShiretoko Nature Foundation, 531 Iwaubetsu, Shari City 099-4356, Hokkaido, Japan.
Masanao NakanishiShiretoko Nature Foundation, 531 Iwaubetsu, Shari City 099-4356, Hokkaido, Japan.
Genta ItoShiretoko Nature Foundation, 531 Iwaubetsu, Shari City 099-4356, Hokkaido, Japan.
Mebuki ItoSchool of Veterinary Medicine Hokkaido University, Kita 18, Nishi 9, Kita-ku, Sapporo City 060-0818, Hokkaido, Japan.
Miku MinamikawaSchool of Veterinary Medicine Hokkaido University, Kita 18, Nishi 9, Kita-ku, Sapporo City 060-0818, Hokkaido, Japan.
Kotaro ShimizuGraduate School of Veterinary Medicine Hokkaido University, Kita 18, Nishi 9, Kita-ku, Sapporo City 060-0818, Hokkaido, Japan.
Koichi GokaNational Institute for Environmental Studies, 16-2 Onogawa, Tsukuba City 305-8506, Ibaraki, Japan.
Manabu OnumaNational Institute for Environmental Studies, 16-2 Onogawa, Tsukuba City 305-8506, Ibaraki, Japan.ORCID https://orcid.org/0000-0001-8611-7506
Keita MatsunoInstitute for Vaccine Research and Development HU-IVReD Hokkaido University, Kita 21, Nishi 11, Kita-ku, Sapporo City 001-0021, Hokkaido, Japan.ORCID https://orcid.org/0000-0002-4205-6526
Toshio TsubotaFaculty of Veterinary Medicine Hokkaido University, Kita 18, Nishi 9, Kita-ku, Sapporo City 060-0818, Hokkaido, Japan.ORCID https://orcid.org/0000-0002-8314-1233

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Various domestic and wildlife species have been found susceptible to and infected with SARS-CoV-2, the causative agent of COVID-19, around the globe, raising concerns about virus adaptation and transmission to new animal hosts. The virus circulation in the white-tailed deer population in North America has further called to action for virus surveillance in the wildlife. Here, we report on the first SARS-CoV-2 survey of wild animals in Japan, where frequent wildlife invasions of urban areas have occurred due to the limited predation, field abandonment, the increase of human acclimatization. Genetic testing using nasal swabs and serological screening have been conducted for sika deer, brown bears, raccoons, and raccoon dogs captured in Hokkaido prefecture from the end of the Delta variant wave to the spread of the Omicron variant, between March 2022 and February 2023. No viral RNA was detected in raccoons (0/184), sika deer (0/107), and brown bears (0/14) indicating that the virus was unlikely to spread within the population of these animal species. Among 171 raccoons, 20 raccoon dogs, 100 sika deer, and 13 brown bears, one raccoon, one brown bear, and two deer tested positive in the antibodies screening with multispecies SARS-CoV-2 N-protein ELISA. Still, ELISA-positive samples tested negative in three other serological tests, emphasizing the importance of confirming serological screening results. Our results suggested that SARS-CoV-2 was unlikely to spillback from humans to wildlife in Hokkaido during the study period, with the emergence of new variants, continuous surveillance is of utmost importance.

Indexed as

Animals, WildCOVID-19SARS-CoV-2AnimalsDeerHumansJapanRaccoon DogsRaccoonsUrsidae

Identifiers

PMID40303042
PMCPMC12016984

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.